Pharmaceuticals & Healthcare

From compulsory licensing to voluntary transfer?

Posted by:

Bristol-Myers Squibb announced a technology transfer agreement with the Brazilian Ministry of Health to expand access to the HIV drug atazanavir. The agreement is designed to build the capacity and skills required for the Brazilian government to become, over time, the sole manufacturer of atazanavir in Brazil.

Does this mark a shift in Brazil’s HIV/AIDS pharmaceutical policy, which in the past was marked by aggressive negotiation with manufacturers and threats of compulsory licensing?

For further details, see:

http://www.news-medical.net/news/20111113/Brazilian-Ministry-of-Health-Bristol-Myers-Squibb-sign-technology-transfer-agreement-for-Reyataz.aspx

http://www.ntn24.com/news/news/brazil-start-producing-anti-hiv-drug

 

Continue Reading →
0

On numbers and access to medicines

Posted by:

Will the proposed Preserve Access to Affordable Generics (PGGA) Act actually generate the $4.8 billion savings over 10 years that the Congressional Budget Office suggests it will? How realistic are its assumptions about generic competition or healthcare costs over the next ten years?

The CBO’s savings estimate of a new bill restricting the use of patent settlement agreements which reward generic manufacturers for delaying market entry and avoid litigation under the ANDA approval pathway is exaggerated. It assumes that savings from ...

Continue Reading →
0

Why not go the whole 9 yards?

Posted by:

If the proposed Preserve Access to Affordable Generics Act will generate savings for the US of $4.8 billion over 10 years (which is much less impressive when calculated on an annual basis, and that is without calculating the costs to the US economy by the negative implications of this legislation), why not go the whole 9 yards and axe the 180 days of market exclusivity to the first generic drug? After all, such a step could generate far greater savings ...

Continue Reading →
0

World’s first malaria vaccine works in major trial

Posted by:

Using IPRs effectively in neglected diseases R&D – What lessons can be learned from the positive results of the GSK and PATH’s Malaria Vaccine Initiative? Allowing partners which contribute proprietary technologies to maintain ownership and income from the end product may be key to achieving tangible results like those of the MVI. In this case, GSK, owner of many of the essential technologies of the vaccine, will supply the final product at a preferred price (cost+5%).This hybrid approach can support ...

Continue Reading →
0
Page 6 of 6 «...23456